New horizons in the treatment of tuberculosis

Biochemical Pharmacology

Volumn 54, Issue 11, 1997, Pages 1165-1172

  Barry III, Clifton E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Drug resistance; Ethambutol; Isoniazid; Methyltransferase; Pyrazinamide; Tuberculosis

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TRANSFERASE;

ANAEROBIC METABOLISM; BACTERIAL METABOLISM; DRUG DEVELOPMENT; DRUG RESISTANCE; DRUG TARGETING; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; MYCOBACTERIUM; MYCOBACTERIUM SMEGMATIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

EID: 0030725891     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00163-9     Document Type: Note

References (84)

1. World Health Organization, TB: Groups at Risk, WHO Report on the Tuberculosis Epidemic. World Health Organization, Geneva, Switzerland, 1996.
2. Dolin PJ, Raviglione MC and Kochi A, Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 72: 213-220, 1994.
3. Bass JB, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, Dixie E, Snider J and Thornton G, Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 149: 1359-1374, 1994.
4. Snider DE Jr and Roper WL, The new tuberculosis. N Engl J Med 326: 703-705, 1992.
5. Bloom BR and Murray CJL, Tuberculosis: Commentary on a reemergent killer. Science 257: 1055-1064, 1992.
6. Bifani PJ, Plidaytis BB, Kapur V, Stockbauer K, Pan X, Lutfey ML, Moghazeh SL, Eisner W, Daniel TM, Kaplan MH, Crawford JT, Musser JM and Kreiswirth BN, Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 275: 452-457, 1996.
7. Wayne LG, Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis 13: 908-914, 1994.
8. Wayne LG and Hayes LG, An in vitro model for sequential study of shiftdown of Mycobocterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64: 2062-2069, 1996.
9. Winder FG, Mode of action of antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria. In: The Biology of the Mycobacteria (Eds. Ratledge C and Standford J), Vol. 1, pp. 353-438. Academic Press, London, 1982.
10. Young DB, Strategies for new drug development. In: Tuberculosis: Pathogenesis, Protection, and Control (Ed. Bloom BR), pp. 559-567. American Society for Microbiology, Washington, DC, 1994.
11. Young DB and Duncan K, Prospects for new interventions in the treatment and prevention of mycobacterial disease. Annu Rev Microbiol 49: 641-673, 1995.
12. Musser JM, Antimicrobial agent resistance in mycobacteria: Molecular genetic insights. Clin Microbiol Rev 8: 496-514, 1995.
13. Cole ST and Telenti A, Drug resistance in Mycobacterium tuberculosis. Eur Respir J 8 (Suppl 20): 701s-713s, 1995.
14. Takayama K and Davidson LA, Isonicotinic acid hydrazide. In: Antibiotics: Mechanism of Action of Antibacterial Agents (Ed. Hahn FE), Vol. I, pp. 98-119. Springer, Berlin, 1979.
15. Zhang Y, Heym B, Allen B, Young D and Cole S, The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358: 591-593, 1992.
16. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D and van Embden JDA, Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: Restricted array of mutations associated with drug resistance. J Infect Dis 173: 196-202, 1996.
17. Zhang Y, Garbe T and Young D, Transformation with katG restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol Microbiol 8: 521-524, 1993.
18. Johnsson K and Schultz PG, Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J Am Chem Soc 116: 7425-7426, 1994.
19. Magliozzo RS and Marcinkeviciene JA, Evidence for isoniazid oxidation by oxyferrous mycobacterial catalase-peroxidase. J Am Chem Soc 118: 11303-11304, 1996.
20. Sherman DR, Mdluli K, Hickey MJ, Arain TM, Morris SL, Barry CE III and Stover CK, Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272: 1641-1643, 1996.
21. Wilson TM, de Lisle GW and Collins DM, Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol 15: 1009-1015, 1995.
22. Christman MF, Morgan RW, Jacobson FS and Ames BN, Positive control of a regulon for defenses against oxidative stress and some heat-shock proteins in Salmonella typhimurium. Cell 41: 753-762, 1985.
23. Sherman DR, Sabo PJ, Hickey MJ, Arain TM, Mahairas GG, Yuan Y, Barry CE III and Stover CK, Disparate responses to oxidative stress in saprophytic and pathogenic mycobacteria. Proc Natl Acad Sci USA 92: 6625-6629, 1995.
24. Deretic V, Philipp W, Dhandayuthapani S, Mudd MH, Curcic R, Garbe T, Heym B, Via LE and Cole ST, Mycobacterium tuberculosis is a natural mutant with an inactivated oxidative-stress regulatory gene: Implications for sensitivity to isoniazid. Mol Microbiol 17: 889-900, 1995.
25. Dussurget O, Rodriguez M and Smith I, An ideR mutant of Mycobacterium smegmatis has derepressed siderophore production and an altered oxidative-stress response. Mol Microbiol 22: 535-544, 1996.
26. Wilson TM and Collins DM, ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Mol Microbiol 19: 1025-1034, 1996.
27. Dhandayuthapani S, Zhang Y, Mudd MH and Deretic V, Oxidative stress response and its role in sensitivity to isoniazid in mycobacteria: Characterization and inducibility of ahpC by peroxides in Mycobacterium smegmatis and lack of expression in M. aurum and M. tuberculosis. J Bacteriol 178: 3641-3649, 1996.
28. Zhang Y, Dhandayuthapani S and Deretic V, Molecular basis for the exquisite sensitivity of Mycobacterium tuberculosis to isoniazid. Proc Natl Acad Sci USA 93: 13212-13216, 1996.
29. Deretic V, Pagan-Ramos E, Zhang Y, Dhandayuthapani S and Via LE, The extreme sensitivity of Mycobacterium tuberculosis to the front-line antituberculosis drug isoniazid. Nature Biotechnol 14: 1557-1561, 1996.
30. Barry CE III and Mdluli K, Drug sensitivity and environmental adaptation of mycobacterial cell wall components. Trends Microbiol 4: 275-281, 1996.
31. Takayama K, Wang L, and David HL, Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2: 29-35, 1972.
32. Takayama K, Schnoes HK, Armstrong EL and Boyle RW, Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J Lipid Res 16: 308-317, 1975.
33. Davidson LA and Takayama K, Isoniazid inhibition of the synthesis of monounsaturated long-chain fatty acids in Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 16: 104-105, 1979.
34. Banerjee A, Duhnau E, Quemard A, Balasuhramanian V, Um KS, Wilson T, Collins D, de Lisle G and Jacobs WR Jr, InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 227-230, 1994.
35. Dessen A, Quenmard A, Blanchard JS, Jacobs WR Jr and Sacchettini JC, Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 267: 1638-1641, 1995.
36. Sacchettini JC and Blanchard JS, The structure and function of the isoniazid target in M. tuberculosis. Res Microbiol 147: 36-43, 1996.
37. Mdluli K, Sherman DR, Hickey MJ, Kreiswirth BN, Morris S, Stover CK and Barry CE III, Biochemical and genetic data suggest that inhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. J Infect Dis 174: 1085-1090, 1996.
38. Cole ST, Rifamycin resistance in mycobacteria. Res Microbiol 147: 48-52, 1996.
39. Telenti A, Imboden P, Marchesi F, Schidheini T and Bodmer T, Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341: 647-650, 1993.
40. Levin ME and Hatfull GF, Mycobacterium smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of refampicin resistance. Mol Microbiol 8: 277-285, 1993.
41. Honore N and Cole ST, Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother 37: 414-418, 1993.
42. Grosset J, Current problems with tuberculosis treatment. Res Microbiol 147: 10-16, 1996.
43. Saito H, Tomioka H, Sato K, Emori M, Yamane T, Yamashita K, Hosoe K and Hidaka T, In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob Agents Chemother 35: 542-547, 1991.
44. Kuze F, Yamamoto T, Amitani R and Suzuki K, In vivo activities of new rifamycin derivatives against mycobacteria. Kekkaku 66: 7-12, 1990.
45. Yamane T, Hashizume T, Yamashita K, Konishi E, Hosoe K, Hidaka T, Watanabe K, Kawaharada H, Yamamoto T and Kuze F, Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chem Pharm Bull (Tokyo) 41: 148-155, 1993.
46. Klemens SP, Grossi MA and Cynamon MH, Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 38: 2245-2248, 1994.
47. Klemens SP and Cynamon MH, Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 40: 298-301, 1996.
48. Yamamoto T, Amitani R, Suzuki K, Tanaka E, Murayama T and Kuze F, In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Antimicrob Agents Chemother 40: 426-428, 1996.
49. Tomioka H, Saito H, Sato K, Yamane T, Yamashita K, Hosoe K, Fujii K and Hidaka T, Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother 36: 387-393, 1992.
50. Mohazeh SL, Pan X, Arain T, Stover CK, Musser JM and Kreiswirth BN, Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 40: 2655-2657, 1996.
51. Konno K, Feldman FM and McDermott W, Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis 95: 461-469, 1967.
52. Butler WR and Kilburn JO, Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity. Antimicrob Agents Chemother 24: 600-601, 1983.
53. Heifets LB, Flory MA and Lindholm-Levy PJ, Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis? Antimicrob Agents Chemother 33: 1252-1254, 1989.
54. Mitchison DA, The action of antituberculosis drugs in short-course therapy. Tubercle 66: 219-225, 1985.
55. Heifets L and Lindholm-Levy P, Pyrazinamide sterilizing activity in vitro against semi-dormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 145: 1223-1225, 1992.
56. Scorpio A and Zhang Y, Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nature Med 2: 662-667, 1996.
57. McDermott W and Tomsett R, Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 70: 748-754, 1954.
58. Cynamon MH, Klemens SP, Chou TS, Gimi RH and Welch JT, Antimycobacterial activity of a series of pyrazinoic acid esters. J Med Chem 35: 1212-1215, 1992.
59. Cynamon MH, Gimi R, Gyenes F, Sharpe CA, Bergmann KE, Han H-J, Gregor LB, Rapolu R, Luciano G and Welch JT, Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity. J Med Chem 38: 3902-3907, 1995.
60. Bergmann KE, Cynamon MH and Welch JT, Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters. J Med Chem 39: 3394-3400, 1996.
61. Takayama K and Kilburn JO, Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 33: 1493-1499, 1989.
62. Wolucka BA, McNeil MR, de Hoffmann E, Chojnacki T and Brennan PJ, Recognition of the lipid intermediated for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. J Biol Chem 269: 23328-23335, 1994.
63. Deng L, Mikusova K, Robuck KG, Scherman M, Brennan PJ and McNeil MR, Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope. Antimicrob Agents Chemother 39: 694-701, 1995.
64. Lee RE, Mikusova K, Brennan PJ and Besra GS, Synthesis of the mycobacterial arabinose donor β-D-arabinofuranosyl-1-monophosphoryl-decaprenol, development of a basic arabinosyl-transferase assay, and identification of ethambutol as an arabinosyl transferase inhibitor. J Am Chem Soc 117: 11829-11832, 1995.
65. Khoo K-H, Douglas E, Azadi P, Inamine JM, Besra GS, Mikusova K, Brennan PJ and Chatterjee D, Truncated structural variants of lipoarabinomannan in ethambutol drug-resistant strains of Mycobacterium smegmatis. J Biol Chem 271: 28682-28690, 1996.
66. Mikusova K, Slayden RA, Besra GS and Brennan PJ, Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother 39: 2484-2489, 1995.
67. Belanger AE, Besra GS, Ford ME, Mikusova K, Belisle JT, Brennan PJ and Inamine JM, The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA 93: 11919-11924, 1996.
68. Maddry JA, Suling WJ and Reynolds RC, Glycosyltransferases as targets for inhibition of cell wall synthesis in M. tuberculosis and M. avium. Res Microbiol 147: 106-112, 1996.
69. Brennan PJ and Nikaido H, The envelope of mycobacteria. Annu Rev Biochem 64: 29-63, 1995.
70. Liu J, Barry CE III, Besra GS and Nikaido H, Mycolic acid structure determines the fluidity of the mycobacterial cell wall. J Biol Chem 271: 29545-29551, 1996.
71. Yuan Y, Lee RE, Besra GS, Belisle JT and Barry CE III, Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 92: 6630-6634, 1995.
72. George KM, Yuan Y, Sherman DR and Barry CE III, The biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis: Identification and functional analysis of CMAS-2. J Biol Chem 270: 27292-27298, 1995.
73. Yuan Y and Barry CE III, A common mechanism for the biosynthesis of methoxy and cyclopropyl mycolic acids in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 93: 12828-12833, 1996.
74. Segal W, Growth dynamics of in vivo and in vitro grown mycobacterial pathogens. In: The Mycobacteria, A Sourcebook, Part A (Eds. Kubica GP and Wayne LG), Vol. 15, pp. 547-573. Marcel Dekker, New York, 1984.
75. Ramakrishnan T, Indira M and Mailer RK, Evaluation of the route of glucose utilization in virulent and avirulent strains of Mycobacterium tuberculosis. Biochim Biophys Acta 59: 529-532, 1962.
76. Yuan Y, Crane DD and Barry CE III, Stationary phase-associated protein expression in Mycobacterium tuberculosis: Function of the mycobacterial α-crystallin homolog. J Bacteriol 178: 4484-4492, 1996.
77. Wayne LG and Lin K-Y, Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 37: 1042-1049, 1982.
78. Wayne LG and Sramek HA, Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 38: 2054-2058, 1994.
79. Edwards DI, Nitroimidazole drugs - Action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 31: 9-20, 1993.
80. Knox RJ, Edwards DI and Knight RC, The mechanism of nitroimidazole damage to DNA: Coulometric evidence. Int J Radiat Oncol Biol Phys 10: 1315-1318, 1984.
81. Sealy RC, Swartz HM and Olive PL, Electron spin resonance-spin trapping detection of superoxide formed during aerobic reduction of nitro compounds. Biochem Biophys Res Commun 82: 680, 1978.
82. Perez-Reyes E, Kalyanaraman B and Mason RP, The reductive metabolism of metronidazole and ornidazole by aerobic liver microsomes. Mol Pharmacol 17: 239-244, 1980.
83. Philipp WJ, Poulet S, Eiglmeier K, Pascopella L, Balasubramanian V, Heym B, Bergh S, Bloom BR, Jacobs WR Jr and Cole ST, An integrated map of the genome of the tubercle bacillus, Mycobacterium tuberculosis H37Rv, and comparison with Mycobacterium leprosy. Proc Natl Acad Sci USA 93: 3132-3137, 1996.
84. Bergh S and Cole ST, MycDB: An integrated mycobacterial database. Mol Microbiol 12: 517-534, 1994.